Targeting protein aggregation for the treatment of degenerative diseases

Nature Reviews. Drug Discovery
Yvonne S EiseleJeffery W Kelly

Abstract

The aggregation of specific proteins is hypothesized to underlie several degenerative diseases, which are collectively known as amyloid disorders. However, the mechanistic connection between the process of protein aggregation and tissue degeneration is not yet fully understood. Here, we review current and emerging strategies to ameliorate aggregation-associated degenerative disorders, with a focus on disease-modifying strategies that prevent the formation of and/or eliminate protein aggregates. Persuasive pharmacological and genetic evidence now supports protein aggregation as the cause of postmitotic tissue dysfunction or loss. However, a more detailed understanding of the factors that trigger and sustain aggregate formation and of the structure-activity relationships underlying proteotoxicity is needed to develop future disease-modifying therapies.

References

Aug 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·M F KnauerC G Glabe
Apr 10, 1992·Science·J A Hardy, G A Higgins
Oct 1, 1991·Trends in Pharmacological Sciences·J Hardy, D Allsop
Apr 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·P WestermarkG G Cornwell
Jan 1, 1985·CRC Critical Reviews in Biochemistry·E A Craig
Jun 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·K S KosikD J Selkoe
Jan 1, 1986·Annual Review of Biochemistry·S Lindquist
Mar 1, 1989·Trends in Neurosciences·M D Benson
Jun 25, 1985·Journal of Molecular Biology·F A FerroneW A Eaton
Dec 1, 1974·Proceedings of the National Academy of Sciences of the United States of America·J HofrichterW A Eaton
Sep 7, 1967·The New England Journal of Medicine·A S Cohen
Sep 1, 1969·Proceedings of the Society for Experimental Biology and Medicine·L BonarM M Skinner
Aug 16, 1984·Biochemical and Biophysical Research Communications·G G Glenner, C W Wong
Jan 1, 1995·Human Mutation·M J Saraiva
Dec 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·K M PanF E Cohen
Aug 1, 1994·Current Opinion in Neurology·L Amaducci, G Tesco
Jun 7, 1994·Proceedings of the National Academy of Sciences of the United States of America·M R HurleR Wetzel
Dec 24, 1996·Proceedings of the National Academy of Sciences of the United States of America·G J MiroyJ W Kelly
Apr 16, 1998·Proceedings of the National Academy of Sciences of the United States of America·K JohanP Westermark
Oct 24, 1998·Bioorganic & Medicinal Chemistry·P W BauresJ W Kelly
Oct 3, 1999·Methods in Enzymology·F Ferrone
Mar 31, 2000·Nature Structural Biology·T KlabundeJ C Sacchettini
Jun 22, 2000·Proceedings of the National Academy of Sciences of the United States of America·P J MuchowskiF U Hartl
Jul 6, 2000·Nature Structural Biology·M P MayerB Bukau

❮ Previous
Next ❯

Citations

Mar 26, 2016·The Journal of Nutritional Biochemistry·Manuela LeriMonica Bucciantini
Jan 7, 2016·Trends in Genetics : TIG·Goran Kungulovski, Albert Jeltsch
Nov 4, 2015·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Margarida D Amaral, William E Balch
Jan 20, 2016·Nature Chemical Biology·Joost Schymkowitz, Frederic Rousseau
Nov 27, 2015·Journal of Molecular Biology·Elizabeth A Sweeny, James Shorter
May 21, 2016·Frontiers in Neuroscience·Rebecca E HughesRona R Ramsay
May 11, 2016·Trends in Pharmacological Sciences·Christian Behl
Jul 28, 2016·Proceedings of the National Academy of Sciences of the United States of America·Timothy S JarvelaIris Lindberg
Oct 25, 2016·Journal of Molecular Biology·Matthias GrohNatalia Gromak
Jan 24, 2017·The International Journal of Neuroscience·Neha SamiMd Imtaiyaz Hassan
Jan 21, 2017·Journal of Liposome Research·Diana Guzman-VillanuevaVolkmar Weissig
Apr 10, 2017·Biochemical Pharmacology·Paul VelanderBin Xu
May 26, 2017·Chemistry : a European Journal·Marina Chemerovski-GlikmanDaniel Segal
Feb 9, 2016·Physical Chemistry Chemical Physics : PCCP·Vasyl YatsynaVitali Zhaunerchyk
Jul 1, 2017·Nature Reviews. Cardiology·Robert H Henning, Bianca J J M Brundel
Mar 2, 2018·Protein Science : a Publication of the Protein Society·Young-Ho Lee, Ayyalusamy Ramamoorthy
Jun 4, 2016·Molecular Biology of the Cell·James Shorter
Jan 30, 2018·Annals of the New York Academy of Sciences·Anoop ArunagiriPeter Arvan
Oct 28, 2017·Expert Opinion on Therapeutic Targets·Mario Nuvolone, Giampaolo Merlini
Sep 25, 2017·Aging Cell·Tokio MatsuzakiMartin K Lotz
Nov 20, 2018·Movement Disorders : Official Journal of the Movement Disorder Society·Antonio Heras-GarvinNadia Stefanova
Jan 16, 2019·Chemistry, an Asian Journal·Zsuzsa SárkányPedro M Martins
Feb 7, 2018·Scientific Reports·Matthew MoldChristopher Exley
Nov 15, 2018·The Journal of Biological Chemistry·Lihan Xie, Ursula Jakob
Mar 17, 2019·International Journal of Molecular Sciences·Anne H S MartinelliRodrigo Ligabue-Braun
May 11, 2019·Protein Science : a Publication of the Protein Society·Kristine Faye R PobreEvan T Powers
Nov 11, 2016·Nature·Roland Riek, David S Eisenberg
Nov 2, 2019·Physical Chemistry Chemical Physics : PCCP·Nidhi Katyal, Shashank Deep
Jan 26, 2020·Antioxidants·Magdalena RudzińskaAndrey A Zamyatnin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Related Papers

Current Opinion in Rheumatology
Niamh P Quillinan, Christopher P Denton
The New England Journal of Medicine
Monte S Willis, Cam Patterson
The New England Journal of Medicine
Darius Ebrahimi-FakhariLara Wahlster
The New England Journal of Medicine
Alessio Galli
© 2021 Meta ULC. All rights reserved